MRVI
Maravai LifeSciences Holdings, Inc.
Biotechnology · Healthcare · United States
7.81
close · 2026-10-30
value
83
cheaper than peers83
quality
61
stronger fundamentals61
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | 21.4% | 98 |
| cash flow yield, 3 years ago | 17.9% | 98 |
| cash flow yield, 2 years ago | 2.1% | 90 |
| cash flow yield, 1 year ago | -0.8% | 80 |
| cash flow yield, latest year | -2.4% | 71 |
| earnings yield, 2 years ago | -11.5% | 58 |
| earnings yield, 1 year ago | -13.4% | 53 |
| earnings yield, latest year | -11.5% | 52 |
| price to sales | 14.13× | 44 |
| price to book | 5.68× | 31 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 1.1% | 81 |
| revenue growth | 40.5% | 62 |
| return on equity | -41.0% | 57 |
| debt to equity | 85.4% | 24 |
4 of 4 measures available
Facts
| market cap | $3B |
| free cash flow | -$11.3M |
| employees | 416 |
| first trade | 2020-11-20 |
| next earnings | 2026-11-04 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.90 | -1.05 | -0.90 | 1.67 |
| free cash flow | -$70.7M | -$22.2M | $60.7M | $518.9M |
| net income | -$130.8M | -$144.8M | -$119.0M | $220.2M |
| revenue | $185.7M | $259.2M | $288.9M | $883.0M |
| unusual items | -$86.7M | -$166.1M | -$3.2M | $7.6M |